bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
307 hedge funds and large institutions have $8.41B invested in bluebird bio in 2018 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 121 increasing their positions, 88 reducing their positions, and 47 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
67% more call options, than puts
Call options by funds: $237M | Put options by funds: $142M
38% more repeat investments, than reductions
Existing positions increased: 121 | Existing positions reduced: 88
11% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 47
1% more funds holding
Funds holding: 303 → 307 (+4)
0.11% more ownership
Funds ownership: 8.14% → 8.25% (+0.11%)
7% less capital invested
Capital invested by funds: $9B → $8.41B (-$594M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$83M |
| 2 |
Millennium Management
New York
|
+$78.6M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$69.2M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$51.7M |
| 5 |
Citigroup
New York
|
+$44.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$199M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$61.8M |
| 3 |
State Street
Boston,
Massachusetts
|
-$50.7M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$49.3M |
| 5 |
Two Sigma Advisers
New York
|
-$42.9M |
BLUE Hedge Fund Activity: Q2 2018 in Review
307 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q2 2018, worth a combined $8.41B — down 6.6% from $9B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new BLUE positions and 47 closed out — a net gain of 5 holders — while 121 added to existing stakes and 88 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $83M. The largest seller was BlackRock, cutting an estimated $199M.
- 307 institutional investors held bluebird bio (BLUE) as of Q2 2018, up from 303 in Q1 2018.
- Funds reported $8.41B of bluebird bio stock for Q2 2018, down 6.6% quarter-over-quarter.
- 52 funds opened new bluebird bio positions in Q2 2018 and 47 closed out, a net change of +5 holders.
- The largest bluebird bio buyer in Q2 2018 was Wellington Management Group, an estimated $83M added.
- The largest bluebird bio seller in Q2 2018 was BlackRock, an estimated $199M sold.
Based on aggregated 13F filings for Q2 2018.